CYB561A3 | Cytochrome b561 family, member A3 | Predicted membrane proteins
| | | | | Expressed in all |
CYB561D1 | Cytochrome b561 family, member D1 | Predicted membrane proteins
| | | | | Mixed |
CYB561D2 | Cytochrome b561 family, member D2 | Predicted membrane proteins
| | | | | Expressed in all |
CYBB | Cytochrome b-245, beta polypeptide | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
CYBRD1 | Cytochrome b reductase 1 | Predicted membrane proteins
| | | | | Expressed in all |
DAGLA | Diacylglycerol lipase, alpha | Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
DCST1 | DC-STAMP domain containing 1 | Predicted membrane proteins
| | | | | Group enriched |
DERL2 | Derlin 2 | Predicted membrane proteins
| | | | | Expressed in all |
DKFZP761J1410 | Lipid phosphate phosphatase-related protein type 2 | Enzymes Predicted membrane proteins
| | | | | Expressed in all |
DNAJC22 | DnaJ (Hsp40) homolog, subfamily C, member 22 | Predicted membrane proteins
| | | | | Tissue enhanced |
DPY19L4 | Dpy-19-like 4 (C. elegans) | Predicted membrane proteins
| | | | | Expressed in all |
DRAM1 | DNA-damage regulated autophagy modulator 1 | Predicted membrane proteins
| | | | | Expressed in all |
DRAM2 | DNA-damage regulated autophagy modulator 2 | Predicted membrane proteins
| | | | | Expressed in all |
EI24 | Etoposide induced 2.4 | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
ELOVL1 | ELOVL fatty acid elongase 1 | Enzymes Predicted membrane proteins
| | | | | Expressed in all |
FITM1 | Fat storage-inducing transmembrane protein 1 | Predicted membrane proteins
| | | | | Group enriched |
FLVCR2 | Feline leukemia virus subgroup C cellular receptor family, member 2 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
FRRS1 | Ferric-chelate reductase 1 | Predicted membrane proteins
| | | | | Mixed |
FZD6 | Frizzled family receptor 6 | Disease related genes G-protein coupled receptors Potential drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
GDPD2 | Glycerophosphodiester phosphodiesterase domain containing 2 | Cytoskeleton related proteins Enzymes Predicted membrane proteins
| | | | | Group enriched |
GGCX | Gamma-glutamyl carboxylase | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
GHITM | Growth hormone inducible transmembrane protein | Predicted membrane proteins
| | | | | Expressed in all |
GHSR | Growth hormone secretagogue receptor | Disease related genes G-protein coupled receptors Potential drug targets Predicted membrane proteins Transporters
| | | | | Not detected |
GPR137 | G protein-coupled receptor 137 | Predicted membrane proteins
| | | | | Expressed in all |
GPR137C | G protein-coupled receptor 137C | Predicted membrane proteins
| | | | | Tissue enriched |
GPR149 | G protein-coupled receptor 149 | G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
GPR153 | G protein-coupled receptor 153 | G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
GPR157 | G protein-coupled receptor 157 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR31 | G protein-coupled receptor 31 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR78 | G protein-coupled receptor 78 | G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
GPR83 | G protein-coupled receptor 83 | G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
GRINA | Glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding) | Predicted membrane proteins
| | | | | Expressed in all |
HGSNAT | Heparan-alpha-glucosaminide N-acetyltransferase | Disease related genes Enzymes Potential drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
HM13 | Histocompatibility (minor) 13 | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
ICMT | Isoprenylcysteine carboxyl methyltransferase | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
INSIG2 | Insulin induced gene 2 | Predicted membrane proteins
| | | | | Expressed in all |
ITPR2 | Inositol 1,4,5-trisphosphate receptor, type 2 | Plasma proteins Predicted membrane proteins
| | | | | Mixed |
JKAMP | JNK1/MAPK8-associated membrane protein | Cancer-related genes Predicted membrane proteins
| | | | | Expressed in all |
KCNA1 | Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNA10 | Potassium voltage-gated channel, shaker-related subfamily, member 10 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNA2 | Potassium voltage-gated channel, shaker-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA3 | Potassium voltage-gated channel, shaker-related subfamily, member 3 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNA4 | Potassium voltage-gated channel, shaker-related subfamily, member 4 | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC3 | Potassium voltage-gated channel, Shaw-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCND1 | Potassium voltage-gated channel, Shal-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCND2 | Potassium voltage-gated channel, Shal-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCND3 | Potassium voltage-gated channel, Shal-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |